Research Article
Comparison of Concomitant Mesalamine and Immunomodulator Therapy and Immunomodulator Monotherapy for Crohn’s Disease
Table 1
Characteristics of the patients.
| | Characteristics | AZA/6-MP
() | AZA/6-MP with 5-ASA () | value |
| | Age, yr, median (IQR) | 30.0 (8.0) | 31.0 (11.0) | 0.290 | | Gender (%) | | | 0.844 | | Male | 81 (76.4) | 240 (75.5) | | | Female | 25 (23.6) | 78 (24.5) | | | Location (%) | | | 0.558 | | L1 (ileal) | 11 (10.4) | 42 (13.3) | | | L2 (colonic) | 4 (3.8) | 16 (5.0) | | | L3 (ileocolonic) | 56 (52.8) | 171 (53.8) | | | L4 (only upper GI) | 0 (0.0) | 0 (0.0) | | | L1–L4 | 6 (5.7) | 21 (6.6) | | | L2–L4 | 2 (1.9) | 1 (0.3) | | | L3-L4 | 25 (23.6) | 64 (20.1) | | | NA | 2 (1.8) | 3 (0.9) | | | Behavior at diagnosis (%) | | | 0.781 | | B1 (nonstricturing, nonpenetrating) | 21 (19.9) | 71 (22.3) | | | B2 (stricturing) | 10 (9.4) | 28 (8.8) | | | B3 (penetrating) | 21 (19.9) | 45 (14.2) | | | B1-P | 27 (26.4) | 87 (27.4) | | | B2-P | 10 (9.4) | 27 (8.5) | | | B3-P | 16 (15.1) | 57 (17.9) | | | NA | 1 (0.9) | 3 (0.9) | | | Previous intestinal resection (%) | 5 (4.7) | 5 (1.6) | 0.130 | | Start year of immunomodulators (%) | | | 0.122 | | 1991–2005 | 7 (6.6) | 38 (11.9) | | | 2006–2014 | 99 (93.4) | 280 (88.1) | | | Previous steroid use (%) | 23 (21.7) | 98 (30.8) | 0.072 | | AZA/6-MP max. tolerable dose, median (IQR) | 1.7 (1.5) | 1.2 (0.8) | <0.001 | | Duration of AZA/6-MP use, mo, median (IQR) | 49.8 (32.0) | 54.6 (31.0) | 0.407 |
|
|
AZA: azathioprine; 6-MP: 6-mercaptopurine; IQR: interquartile range; GI: gastrointestinal; NA: not applicable.
|
